ExodusPoint Capital Management LP Purchases Shares of 33,598 UroGen Pharma Ltd. (NASDAQ:URGN)

ExodusPoint Capital Management LP purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 33,598 shares of the company's stock, valued at approximately $358,000. ExodusPoint Capital Management LP owned 0.14% of UroGen Pharma as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in UroGen Pharma by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock valued at $4,919,000 after buying an additional 6,265 shares during the period. Alliancebernstein L.P. grew its stake in shares of UroGen Pharma by 751.5% in the 4th quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock worth $2,122,000 after buying an additional 175,859 shares during the last quarter. Wellington Management Group LLP raised its stake in UroGen Pharma by 7.0% during the fourth quarter. Wellington Management Group LLP now owns 146,953 shares of the company's stock valued at $1,565,000 after buying an additional 9,653 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma in the fourth quarter worth $59,000. Finally, Rosalind Advisors Inc. bought a new position in shares of UroGen Pharma during the fourth quarter valued at $9,266,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

URGN has been the topic of several recent analyst reports. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. HC Wainwright decreased their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. The Goldman Sachs Group cut their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday. Finally, Scotiabank assumed coverage on shares of UroGen Pharma in a report on Wednesday. They issued a "sector outperform" rating and a $23.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, UroGen Pharma currently has a consensus rating of "Buy" and an average target price of $32.86.

Insiders Place Their Bets

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares of the company's stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company's stock.

UroGen Pharma Stock Performance

Shares of NASDAQ URGN traded down $0.72 during trading on Friday, reaching $9.67. 741,549 shares of the company traded hands, compared to its average volume of 510,367. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 12-month low of $8.94 and a 12-month high of $20.70. The firm's fifty day simple moving average is $10.50 and its 200 day simple moving average is $11.21. The stock has a market cap of $445.73 million, a P/E ratio of -3.07 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. As a group, research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.